Xspray Pharma Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Xspray Pharma kazanç ve gelirinin sırasıyla yıllık 134.8% ve 134.5% oranında artması tahmin edilirken, EPS'nin yıllık 126.6% oranında büyümesi bekleniyor.

Anahtar bilgiler

134.8%

Kazanç büyüme oranı

126.6%

EPS büyüme oranı

Biotechs kazanç büyümesi	45.7%
Gelir büyüme oranı	134.5%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	07 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

OM:XSPRAY - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (SEK Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	1,618	818	N/A	N/A	2
12/31/2025	498	-60	-154	-60	2
12/31/2024	5	-216	-283	-198	1
9/30/2024	N/A	-258	-232	-193	N/A
6/30/2024	N/A	-215	-259	-221	N/A
3/31/2024	N/A	-213	-257	-213	N/A
12/31/2023	N/A	-180	-256	-203	N/A
9/30/2023	N/A	-180	-268	-206	N/A
6/30/2023	N/A	-170	-242	-160	N/A
3/31/2023	N/A	-148	-223	-128	N/A
12/31/2022	N/A	-132	-238	-110	N/A
9/30/2022	N/A	-128	-216	-85	N/A
6/30/2022	N/A	-114	-198	-79	N/A
3/31/2022	N/A	-102	-185	-67	N/A
12/31/2021	N/A	-97	-148	-52	N/A
9/30/2021	N/A	-60	-146	-53	N/A
6/30/2021	N/A	-57	-145	-49	N/A
3/31/2021	N/A	-56	-141	-46	N/A
12/31/2020	N/A	-52	-141	-48	N/A
9/30/2020	N/A	-56	-141	-48	N/A
6/30/2020	N/A	-55	-140	-44	N/A
3/31/2020	N/A	-49	-135	-35	N/A
12/31/2019	N/A	-46	-126	-34	N/A
9/30/2019	-22	-41	-115	-29	N/A
6/30/2019	-14	-34	-97	-24	N/A
3/31/2019	-6	-30	-91	-27	N/A
12/31/2018	0	-23	-65	-18	N/A
9/30/2018	31	-17	-62	-25	N/A
6/30/2018	28	-16	N/A	-12	N/A
3/31/2018	29	-8	N/A	-7	N/A
12/31/2017	0	-14	N/A	-12	N/A
9/30/2017	35	1	N/A	12	N/A
6/30/2017	30	-3	N/A	-2	N/A
3/31/2017	21	-7	N/A	-6	N/A
12/31/2016	21	-4	N/A	-2	N/A
12/31/2015	5	-12	N/A	-13	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: XSPRAY önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 1.2% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: XSPRAY önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: XSPRAY önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: XSPRAY şirketinin gelirinin (yıllık 134.5% ) Swedish pazarından (yıllık -0% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: XSPRAY şirketinin gelirinin (yıllık 134.5% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: XSPRAY 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Xspray Pharma Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target decreased by 24% to kr91.50

Price target decreased by 11% to kr107

Price target decreased by 21% to kr106

Forecast to breakeven in 2024

Price target decreased to kr116

Forecast to breakeven in 2024

Recent updates

Xspray Pharma AB (publ) to Report Fiscal Year 2024 Final Results on Mar 27, 2025

Xspray Pharma AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 135.04904 million.

Xspray Pharma AB (publ), Annual General Meeting, May 13, 2025

Xspray Pharma AB's Nomination Committee for the Annual General Meeting 2025

Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission

New major risk - Financial position

Director recently bought kr4.8m worth of stock

Price target decreased by 24% to kr91.50

New major risk - Share price stability

Xspray Pharma Ab's Xs003 Study Shows Matching Bioavailability to Tasigna At More Than A 50% Lower Dose

Director recently bought kr143k worth of stock

Now 32% undervalued

Now 23% undervalued

Price target decreased by 11% to kr107

New minor risk - Share price stability

Insufficient new directors

Xspray Pharma AB (publ) Announces to Present Data At ASCO Highlighting Frequent Decideication of PPIs with TKIs in CML-Patients and Greater Than Expected Positive Effects on the Bioavailability of Crystalline Dasatinib

Director recently bought kr504k worth of stock

Chief Executive Officer recently sold kr75k worth of stock

Chairman exercised options to buy kr24m worth of stock.

Xspray Pharma AB (publ) to Report Fiscal Year 2024 Results on Feb 12, 2025

New minor risk - Share price stability

We Think Xspray Pharma (STO:XSPRAY) Needs To Drive Business Growth Carefully

Xspray Pharma AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

New major risk - Revenue and earnings growth

FDA Accepts Xpray Pharma's NDA-Resubmission for Dasynoc® - PDUFA

Xspray Pharma AB (publ) Appoints Kerstin Hasselgren as Head of IR

Director recently bought kr2.1m worth of stock

Independent Director exercised options to buy kr97k worth of stock.

Xspray Pharma Ab's Xs003 Achieves Superior Bioavailability Milestone, Matching TASIGNA At Reduced Dosage

Director recently bought kr5.0m worth of stock

Xspray Pharma AB Through HyNap™ technology Announces Results from Drug Interaction Studies

Xspray Pharma AB (publ), Annual General Meeting, May 21, 2024

New major risk - Financial position

Xspray Pharma Appoints Edward P. Jordan as Chief Commercial Officer

Xspray Pharma and Bristol Myers Squibb Reach Settlement on Dasynoc Patent Litigation, Paving Way for Early Market Launch

Xspray Pharma AB (publ) to Report Q4, 2023 Results on Feb 14, 2024

Xspray Pharma AB (publ) Receives Request for Additional Information Concerning Dasynoc from FDA

Price target decreased by 21% to kr106

Chief Executive Officer recently sold kr2.2m worth of stock

Director recently bought kr135k worth of stock

Xspray Pharma AB (publ) to Report Fiscal Year 2022 Final Results on Mar 29, 2023

Director recently bought kr2.6m worth of stock

Xspray Pharma AB (publ)'s Drug Candidate Xs004 Granted Orphan Drug Designation in the US for the Treatment of Acute Lymphoblastic Leukemia

Forecast to breakeven in 2024

Xspray Pharma AB (publ), Annual General Meeting, May 16, 2023

Xspray Pharma AB Appoints Thomas Walz to the Newly Established Position Chief Medical Officer

Xspray Pharma AB (publ) Approves Election of Robert Molander as Member of its Board of Directors

We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

Xspray Pharma AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023

Price target decreased to kr116

Forecast to breakeven in 2024

Xspray Pharma AB (publ), Annual General Meeting, May 19, 2022

Xspray Pharma AB (Publ) Appoints Anna-Karin as Global Head of Marketing and Sales, Effective March 15, 2022

We Think Xspray Pharma (STO:XSPRAY) Can Afford To Drive Business Growth

Xspray Pharma AB (Publ) Announces Fda Allows Review of Application for Market Approval for Dasynoc™

Price target decreased to kr116

No longer forecast to breakeven

We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

Independent Chairman of the Board Michael Jensen has left the company

We're Hopeful That Xspray Pharma (STO:XSPRAY) Will Use Its Cash Wisely

New 90-day low: kr113

Xspray Pharma AB (publ) Announces Nomination Committee for the AGM 2021

Do Institutions Own Xspray Pharma AB (publ) (STO:XSPRAY) Shares?

New 90-day low: kr114

Chief Executive Officer exercised options and sold kr3.6m worth of stock

Xspray Pharmas study with modified formulation of HyNap-Dasa has now started

New 90-day low: kr127